J Pharmacol Exp Ther 289, 321-328, (1999a). Soriani, O., Foll, F. L., Roman, F., Monnet, F. P., Vaudry, H., & Cazin, L. View abstract in PubMed Post navigationPreviousPrevious post:Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan.NextNext post:Olfactory bulbectomy increases prepro-enkephalin mRNA levels in the ventral striatum in rats.Related PostsAnavex Life Sciences Receives Michael J. Fox Foundation Grant for Clinical Study of ANAVEX®2-73 (blarcamesine) in People with Parkinson’s DiseaseJanuary 11, 2021Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect ConferenceJanuary 6, 2021Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program UpdatesDecember 28, 2020Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020December 22, 2020
Anavex Life Sciences Receives Michael J. Fox Foundation Grant for Clinical Study of ANAVEX®2-73 (blarcamesine) in People with Parkinson’s DiseaseJanuary 11, 2021
Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program UpdatesDecember 28, 2020
Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020December 22, 2020
